hantavirus
envelop
rna
virus
belong
famili
bunyaviridia
human
give
rise
spectrum
ill
call
hemorrhag
fever
renal
syndrom
hfr
eurasia
hantaviru
cardiopulmonari
syndrom
hcp
america
hcp
carri
mortal
rate
wherea
mortal
hfr
lower
incid
hfr
substanti
higher
classic
hfr
occur
distinct
phase
febril
hypotens
oligur
polyur
convalesc
capillari
leakag
thrombocytopenia
acut
kidney
injuri
aki
key
element
pathogenesi
hfr
specif
treatment
avail
hantaviru
infect
low
platelet
count
hallmark
hantaviru
diseas
sever
bleed
symptom
vari
accord
hantaviru
speci
sign
bleed
note
onethird
patient
infect
common
european
hantaviru
puumala
viru
puuv
hemorrhag
document
variou
organ
fatal
case
mild
mucocutan
involv
report
gener
howev
thromboembol
complic
increas
risk
acut
myocardi
infarct
stroke
report
associ
puuvinduc
hfr
swedish
patient
individu
balanc
enhanc
hamper
coagul
prevail
remain
challeng
recent
studi
support
idea
platelet
contribut
diseas
progress
bind
fibrincov
endotheli
cell
mechan
lead
decreas
platelet
count
acut
hantaviru
infect
upregul
tissu
factor
tf
express
infect
endotheli
cell
suggest
induc
increas
thrombin
format
note
puuv
infect
compat
endotheli
cell
activ
elev
level
tissu
plasminogen
activ
ddimer
observ
find
enhanc
platelet
ligand
concord
increas
platelet
activ
larg
mean
platelet
volum
mpv
immatur
platelet
fraction
ipf
togeth
elev
serum
thrombopoietin
tpo
level
impli
activ
thrombopoiesi
despit
increas
platelet
product
aggreg
howev
impair
studi
serum
tpo
level
procoagul
activ
plasma
microparticl
mp
finnish
patient
treat
hospit
acut
puuv
infect
analyz
result
relat
clinic
data
platelet
function
test
whole
blood
platelet
function
analyz
multipl
coagul
variabl
avail
aim
studi
whether
activ
thrombopoiesi
could
confirm
thrombocytopenia
associ
acut
hantaviru
infect
also
sought
character
procoagul
chang
observ
vitro
vivo
predict
diseas
sever
still
utmost
import
treatment
hantaviru
infect
particularli
compar
relationship
find
clinic
diseas
sever
studi
carri
tamper
univers
hospit
univers
tamper
school
medicin
finland
patient
came
pirkanmaa
region
hospit
serolog
confirm
acut
puuv
infect
period
octob
novemb
written
inform
consent
obtain
patient
ethic
committe
tamper
univers
hospit
approv
studi
protocol
studi
group
consist
prospect
collect
consecut
adult
patient
male
median
age
year
rang
year
twentynin
patient
also
particip
previou
studi
determin
platelet
indic
function
acut
puuv
infect
concomit
diseas
includ
arteri
hypertens
n
diabet
mellitu
n
hypercholesterolemia
n
coronari
heart
diseas
n
sleep
apnea
n
celiac
diseas
n
one
patient
chronic
obstruct
pulmonari
diseas
patient
undergon
splenectomi
hereditari
spherocytosi
patient
immunosuppress
anticoagul
two
patient
receiv
antiplatelet
therapi
acetylsalicyl
acid
mg
daili
follow
variabl
record
smoke
yesno
number
day
onset
fever
acut
phase
sampl
collect
lowest
diastol
systol
blood
pressur
mmhg
clinic
diagnosi
shock
yesno
sign
bleed
yesno
thromboembol
complic
yesno
infus
platelet
yesno
need
transient
hemodialysi
treatment
yesno
maximum
minimum
daili
urinari
output
ml
gain
weight
kg
last
variabl
reflect
fluid
retent
hospit
stay
oligur
phase
diseas
complet
blood
count
creactiv
protein
crp
creatinin
alanin
aminotransferas
alt
measur
plasma
sampl
accord
clinic
need
laboratori
analys
carri
laboratori
centr
pirkanmaa
hospit
district
use
standard
method
serum
sampl
measur
tpo
level
acut
phase
diseas
collect
median
day
rang
day
begin
fever
citrat
plasma
measur
procoagul
activ
mp
coagul
variabl
plasma
fibrinogen
prothrombin
fragment
ddimer
well
whole
blood
platelet
indic
mpv
ipf
function
multipl
collect
time
median
day
rang
day
begin
fever
control
sampl
obtain
recoveri
visit
median
day
rang
day
begin
fever
tpo
blood
sampl
collect
centrifug
minut
serum
frozen
human
thrombopoietin
immunoassay
quantikin
elisa
appli
accord
manufactur
instruct
r
system
minneapoli
mn
healthi
volunt
n
mean
level
serum
tpo
pgml
rang
nondetect
pgml
accord
manufactur
measur
procoagul
activ
mp
plasma
citrateanticoagul
nmoll
sodium
citrat
blood
sampl
centrifug
minut
plasma
separ
centrifug
minut
frozen
blood
sampl
process
plasma
accord
instruct
zymyphen
mpactiv
elisa
aniara
hyphen
biom
west
chester
oh
appli
analys
mp
activ
test
kit
function
assay
measur
procoagul
activ
mp
deriv
variou
cellular
sourc
assay
circul
mp
plasma
sampl
bind
annexin
v
micropl
surfac
expos
phospholipid
surfac
allow
prothrombin
activ
factor
xa
va
complex
presenc
calcium
expos
phospholipid
concentr
reflect
amount
thrombin
gener
measur
use
specif
thrombin
substrat
accord
manufactur
concentr
mp
normal
plasma
usual
nmoll
express
phophatidylserin
equival
measur
mpv
ipf
well
assess
platelet
function
multipl
describ
detail
recent
articl
fibrinogen
measur
modif
clauss
method
multifibren
u
siemen
healthcar
diagnost
ddimer
immunoturbidimetr
assay
tinaqu
ddimer
roch
diagnost
mannheim
germani
enzym
immunoassay
enzygnost
monoclon
siemen
healthcar
diagnost
refer
valu
gl
fibrinogen
mgl
ddimer
pmoll
sinc
continu
variabl
skew
median
rang
calcul
describ
data
number
percentag
use
categor
variabl
comparison
group
base
u
test
test
evalu
chang
acut
recoveri
phase
wilcoxon
test
use
relationship
continu
variabl
examin
use
spearman
rank
correl
coeffici
limit
signific
set
ibm
spss
statist
window
version
ibm
corp
armonk
ny
use
comput
patient
suffer
clinic
typic
serolog
confirm
puuv
infect
examin
hospit
acut
phase
ill
patient
recov
tabl
present
clinic
basic
laboratori
find
studi
patient
eighteen
patient
smoker
ten
patient
sign
bleed
tendenc
mostli
mild
mucos
bleed
thromboembol
complic
observ
time
control
recoveri
phase
visit
three
patient
receiv
platelet
transfus
four
patient
clinic
shock
time
admiss
ie
systol
blood
pressur
mmhg
togeth
clinic
symptom
sign
shock
two
patient
need
transient
hemodialysi
one
anoth
patient
treat
intens
care
unit
time
acut
phase
tpo
mp
sampl
patient
platelet
count
cellsl
median
cellsl
rang
cellsl
timepoint
median
creatinin
valu
patient
rang
control
recoveri
phase
sampl
platelet
count
patient
recov
patient
exceed
lower
limit
refer
rang
cellsl
median
rang
cellsl
serum
tpo
level
nearli
higher
acut
compar
control
tabl
find
elev
serum
tpo
level
acut
phase
diseas
remain
patient
divid
group
median
valu
base
platelet
count
time
tpo
measur
lowest
platelet
count
fig
larg
mpv
ipf
coincid
elev
serum
tpo
level
tabl
associ
note
serum
tpo
level
ipf
r
p
high
serum
tpo
level
coincid
still
thrombocytopenia
associ
impair
platelet
function
studi
whole
blood
fig
multipl
acut
phase
diseas
howev
closur
time
studi
slightli
prolong
acut
compar
control
despit
lower
platelet
count
tabl
platelet
function
studi
multipl
describ
detail
elsewher
high
serum
tpo
associ
impair
aggreg
trigger
agonist
adrenalin
r
p
adenosin
diphosph
r
p
arachidon
acid
r
p
collagen
r
p
thrombin
receptoractiv
peptid
r
p
ristocetin
r
p
serum
tpo
level
associ
length
hospit
stay
r
p
neg
associ
prevail
tpo
minimum
hematocrit
r
p
platelet
count
time
tpo
measur
r
p
minimum
platelet
count
r
p
sign
bleed
tendenc
howev
associ
serum
tpo
level
associ
found
serum
acutephas
tpo
level
plasma
creatinin
minimum
maximum
daili
urinari
output
gain
weight
need
transient
hemodialysi
minimum
systol
diastol
blood
pressur
smoke
associ
serum
tpo
level
either
data
shown
ddimer
higher
acut
compar
valu
measur
control
visit
group
puuvinfect
patient
clearli
elev
tabl
associ
serum
tpo
level
r
p
ddimer
associ
minimum
platelet
count
r
p
r
p
respect
plasma
creatinin
level
time
measur
r
p
r
p
respect
maximum
plasma
creatinin
r
p
r
p
respect
differ
activ
mp
deriv
variou
cellular
origin
acut
phase
puuv
infect
compar
recoveri
phase
associ
mp
clinic
laboratori
variabl
determin
studi
could
observ
howev
patient
plasma
creatinin
valu
median
mp
procoagul
activ
increas
acut
compar
control
median
nmoll
rang
nmoll
vs
median
nmoll
rang
nmoll
p
likewis
mp
activ
increas
acut
among
patient
maximum
plasma
creatinin
valu
median
median
nmoll
rang
nmoll
vs
median
nmoll
rang
nmoll
p
mp
activ
acut
phase
diseas
differ
activ
observ
recoveri
patient
divid
group
median
valu
base
platelet
count
time
mp
activ
measur
lowest
platelet
count
two
patient
sever
ill
laboratori
find
describ
tabl
patient
previous
smoke
male
need
intens
care
treatment
patient
smoke
male
need
temporari
hemodialysi
treatment
patient
low
platelet
count
minimum
high
acut
tpo
ipf
prolong
closur
time
measur
evid
find
studi
elev
level
serum
tpo
acut
puuv
infect
compar
recoveri
phase
elev
platelet
indic
mpv
ipf
impli
bone
marrow
respons
tpo
stimulu
adequ
decreas
platelet
count
observ
acut
phase
diseas
contribut
factor
impair
platelet
product
associ
high
tpo
decreas
platelet
function
measur
multipl
observ
thrombocytopenia
suggest
activ
thrombopoiesi
though
abl
provid
clinic
hemostasi
suffici
overcom
diminish
function
capac
note
vitro
tpo
associ
aki
major
outcom
hfr
markedli
increas
ddimer
support
idea
platelet
consumpt
vasculatur
ongo
coagul
fibrinolysi
associ
variabl
reflect
aki
novel
find
finnish
puuvpati
line
previou
observ
high
ddimer
sever
diseas
condit
swedish
patient
could
detect
increas
mp
procoagul
activ
acut
puuv
infect
find
howev
need
explor
detail
mp
shown
bind
fibrin
surfac
may
case
hantaviru
infect
tpo
humor
growth
factor
character
abil
stimul
product
differenti
megakaryocyt
tpo
mainli
produc
liver
kidney
bind
tpo
receptor
cmpl
platelet
surfac
initi
intracellular
signal
includ
activ
transduc
activ
transcript
stat
pathway
plasma
tpo
concentr
vari
usual
invers
platelet
count
mechan
platelet
count
affect
tpo
also
identifi
high
plasma
concentr
tpo
low
platelet
count
report
patient
puumala
hantaviru
dengu
viru
human
immunodefici
viru
hiv
infect
hivinfect
patient
cmpl
express
per
platelet
elev
recombin
human
megakaryocyt
growth
factor
reduc
cmpl
express
restor
platelet
count
normal
level
macaqu
model
hiv
transform
growth
factor
downregul
tpo
combin
antiretrovir
therapi
correct
plasma
level
platelet
count
sever
acut
respiratori
syndrom
induc
novel
coronaviru
inhibit
effect
high
tpo
megakaryocytopoiesi
inflammatori
mediat
interleukin
howev
increas
tpo
product
vitro
vivo
find
high
tpo
acut
puuv
infect
line
previou
observ
consist
low
platelet
count
high
plasma
acut
puuv
infect
high
plasma
level
tpo
suggest
predict
sepsi
sever
earli
diseas
phase
note
associ
plasma
level
tpo
length
hospit
stay
latter
variabl
describ
overal
diseas
sever
howev
studi
tpo
associ
variabl
reflect
aki
major
clinic
determin
hantavirusinduc
hfr
invers
associ
serum
tpo
level
platelet
function
measur
multipl
clear
posit
associ
tpo
ipf
tpo
report
enhanc
platelet
activ
burn
injuri
increas
platelet
adhes
flow
moreov
high
tpo
prime
effect
platelet
aggreg
respons
differ
agonist
studi
effect
low
platelet
count
platelet
aggreg
compens
simultan
occur
elev
tpo
level
high
proport
young
platelet
major
bleed
problem
avoid
thromboembol
complic
note
hemostasi
appear
clinic
balanc
spite
laboratori
find
reflect
impair
primari
hemostasi
mp
exosom
small
membran
vesicl
releas
differ
cell
type
exocyt
bud
respons
cellular
activ
apoptosi
seen
mediat
celltocel
commun
express
phospholipid
classic
thought
function
procoagul
support
thrombin
format
facilit
coagul
factor
viitfdepend
independ
pathway
elev
concentr
mp
deriv
platelet
endotheli
cell
monocyt
report
arteri
venou
thrombot
diseas
well
autoimmun
condit
infecti
diseas
hematolog
disord
cancer
howev
clinic
signific
find
remain
controversi
flow
cytometri
wide
use
method
studi
mp
increas
tf
express
enhanc
thrombin
format
sign
cellular
activ
apoptosi
present
acut
hantaviru
infect
presum
detect
higher
level
mp
procoagul
activ
acut
phase
diseas
compar
recoveri
phase
howev
find
among
patient
mild
kidney
injuri
studi
increas
thrombin
format
fibrinolysi
ddimer
associ
sever
aki
attach
plateletderiv
mp
fibrin
clot
especi
patient
sever
kidney
injuri
could
plausibl
explain
observ
preanalyt
measur
well
analyt
method
detect
mp
activ
crucial
even
instruct
elisaassay
manufactur
vigor
follow
issu
regard
methodolog
complet
exclud
sampl
size
studi
though
larg
probabl
suffici
differ
serum
tpo
level
acut
phase
diseas
compar
recoveri
could
verifi
mp
procoagul
activ
associ
variabl
depict
diseas
sever
fail
predict
clinic
outcom
group
patient
acut
puumala
hantaviru
infect
plasma
level
tpo
mp
activ
could
predict
sever
hantaviru
diseas
patient
studi
sever
ill
patient
particularli
high
tpo
level
percentag
young
platelet
well
clearli
impair
platelet
function
accord
acut
phase
diseas
tabl
find
regard
mp
activ
individu
patient
inconsist
may
stem
patient
medic
histori
current
treatment
well
condit
conclus
serum
tpo
upregul
product
platelet
enhanc
acut
puumala
hantaviru
diseas
serum
tpo
predict
diseas
sever
term
aki
biomark
thrombin
gener
especi
fibrinolysi
high
absenc
clinic
thrombosi
major
bleed
associ
advers
kidney
outcom
thrombopoiesi
activ
proport
young
platelet
high
measur
activ
plateletderiv
mp
flow
cytometri
might
clarifi
role
mp
pathogenesi
hfr
